Table 1.
Demographic and biological characteristics of registered Chilean NET patients. * Thoracic NET cases includes broncho/pulmonary and thymic tumors; ** unknown site NETs include breast (not primary) and other with uncertain origin
| All patients | GEP | Pancreatic | Gastric | Small bowel | Colorectal | Appendicular | Hepatobiliary | Thoracic* | Unknown** | |
|---|---|---|---|---|---|---|---|---|---|---|
| Median age/years (range) | 53 (22–85) | 52 (25–81) | 48 (25–78) | 58 (29–81) | 55 (27–77) | 52.5 (25–70) | 42 (28–63) | 60 (49–71) | 46 (22–73) | 61 (33–75) |
| Median OS/months | 110 | 168 | ND | 31 | 168 | 83 | ND | ND | ND | 68 |
| 5-year OS rate (%) | 71.5 | 78.5 | 75.1 | ND | 86.5 | 68.8 | ND | ND | 70 | 50 |
| Gender n (%) | 166 (100) | 115 (100) | 35 (100) | 9 (100) | 53 (100) | 12 (100) | 4 (100) | 2 (100) | 11 (100) | 9 (100) |
| Male | 90 (54) | 64 (56) | 21 (60) | 4 (44.4) | 32 (60) | 5 (41.7) | 1 (25) | 1 (50) | 7 (63.6) | 3 (33.3) |
| Female | 76 (46) | 51 (44) | 14 (40) | 5 (55.6) | 21 (40) | 7 (58.3) | 3 (75) | 1 (50) | 4 (36.4) | 6 (66.7) |
| Tumor stage n (%) | 145 (100) | 102 (100) | 30 (100) | 7 (100) | 51 (100) | 9 (100) | 3 (100) | 2 (100) | 11 (100) | 8 (100) |
| Stage I | 17 (12) | 14 (14) | 4 (13.3) | 4 (57.1) | 3 (5.9) | 1 (11.1) | 2 (66.7) | 0 (0) | 3 (27.3) | 0 |
| Stage II | 17 (12) | 8 (8) | 4 (13.3) | 0 | 3 (5.9) | 0 | 1 (33.3) | 0 (0) | 2 (18.2) | 3 (37.5) |
| Stage III | 21 (14) | 16 (15) | 5 (16.7) | 0 | 8 (15.7) | 2 (22.2) | 0 | 1 (50) | 1 (9.1) | 0 |
| Stage IV | 90 (62) | 64 (63) | 17 (56.7) | 3 (42.9) | 37 (72.5) | 6 (66.7) | 0 | 1 (50) | 5 (45.5) | 5 (62.5) |
| ECOG n (%) | 129 (100) | 82 (100) | 25 (100) | 6 (100) | 40 (100) | 7 (100) | 3 (100) | 2 (100) | 10 (100) | 8 (100) |
| 0 | 49 (38) | 32 (39) | 10 (40) | 2 (33.3) | 16 (40) | 1 (14.3) | 3 (100) | 1 (50) | 4 (40) | 1 (12.5) |
| 1 | 69 (54) | 43 (52) | 13 (52) | 3 (50) | 20 (50) | 6 (85.7) | 0 | 1 (50) | 6 (60) | 6 (75) |
| 2 | 7 (5) | 6 (8) | 2 (8) | 1 (16.7) | 3 (7.5) | 0 | 0 | 0 | 0 | 1 (12.5) |
| 3 | 4 (3) | 1 (1) | 0 | 0 | 1 (2.5) | 0 | 0 | 0 | 0 | 0 |
| Tumor grade n (%) | 159 (100) | 111 (100) | 34 (100) | 8 (100) | 51 (100) | 12 (100) | 4 (100) | 2 (100) | 10 (100) | 8 (100) |
| 1 | 90 (56) | 67 (60) | 21 (61.8) | 2 (25) | 36 (70.6) | 6 (50) | 2 (50) | 0 | 5 (50) | 2 (25) |
| 2 | 34 (22) | 31 (28) | 10 (29.4) | 3 (37.5) | 14 (27.4) | 4 (33.3) | 0 | 0 | 0 | 0 |
| 3 | 35 (22) | 13 (12) | 3 (8.8) | 3 (37.5) | 1 (2) | 2 (16.7) | 2 (50) | 2 (100) | 5 (50) | 6 (75) |
| Ki-67 n (%) | 92 (100) | 71 (100) | 19 (100) | 8 (100) | 29 (100) | 9 (100) | 4 (100) | 2 (100) | 8 (100) | 4 (100) |
| 0–2% | 27 (29) | 25 (35) | 6 (31.6) | 4 (50) | 13 (44.8) | 3 (33.3) | 3 (75) | 0 | 2 (25) | 0 |
| 3–20% | 39 (43) | 33 (47) | 9 (47.4) | 4 (50) | 15 (51.7) | 5 (55.6) | 0 | 0 | 2 (25) | 1 (25) |
| > 20% | 26 (28) | 13 (18) | 4 (21) | 0 | 1 (3.5) | 1 (1.1) | 1 (25) | 2 (100) | 4 (50) | 3 (75) |
| CgA n (%) | 57 (100) | 52 (100) | 21 (100) | 3 (100) | 23 (100) | 3 (100) | 0 | 2 (100) | 3 (100) | 1 (100) |
| < 100 ng/mL | 27 (47) | 23 (44) | 8 (38.1) | 1 (33.3) | 12 (52.2) | 2 (66.7) | 0 | 0 | 2 (66.7) | 1 (100) |
| > 100 ng/mL | 30 (53) | 29 (56) | 13 (61.9) | 2 (66.7) | 11 (47.8) | 1 (33.3) | 0 | 2 (100) | 1 (33.3) | 0 |
| I-P serotonin n (%) | 45 (100) | 43 (100) | 8 (100) | 1 (100) | 30 (100) | 4 (100) | 0 | 0 | 0 | 0 |
| 400–800 ng/109 plat. | 12 (27) | 10 (23) | 2 (25) | 0 | 6 (20) | 2 (50) | 0 | 0 | 0 | 0 |
| > 800 ng/109 plat. | 33 (73) | 33 (77) | 6 (75) | 1 (100) | 24 (80) | 2 (50) | 0 | 0 | 0 | 0 |
| 5-HIAA n (%) | 52 (100) | 49 (100) | 11 (100) | 0 | 33 (100) | 4 (100) | 0 | 0 | 0 | 0 |
| < 100 μmol/h | 21 (40) | 18 (37) | 7 (63.6) | 0 | 8 (24.2) | 2 (50) | 0 | 0 | 0 | 0 |
| > 100 μmol/h | 31 (60) | 31 (63) | 4 (36.4) | 0 | 25 (75.8) | 2 (50) | 0 | 0 | 0 | 0 |